Cat. No. 3830
Chemical Name: 4,4'-(Carbonylbis(imino-3,1-(4-methy
Biological ActivityP2Y11 antagonist; exhibits 520-fold selectivity for P2Y11 over P2Y1, P2Y2, P2Y4, P2Y6 and P2Y12 receptors. Displays competitive antagonism against ATPγS (pIC50 values are 6.43 and 7.14 in Ca2+ and cAMP assays respectively).
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
Meis et al (2010) NF546 [4,4'-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)-carbonylimino))-bis(1,3-xylene-γ,γ'-diphosphonic acid) tetrasodium salt] is a non-nucleotide P2Y11 agonist and stimulates release of interleukin-8 from human monocyte-derived dendritic cells. J.Pharmacol.Exp.Ther. 332 238. PMID: 19815812.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for NF 340 include:
Barragán-Iglesias et al (2014) Role of spinal P2Y6 and P2Y11 receptors in neuropathic pain in rats: possible involvement of glial cells. Mol Pain 10 29. PMID: 24886406.
Gao et al (2013) The role of P2Y(14) and other P2Y receptors in degranulation of human LAD2 mast cells. Autophagy 9 31. PMID: 22825617.
Do you know of a great paper that uses NF 340 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: NF 340, supplier, P2Y11, purinoceptors, purines, receptors, antagonists, NF340, Tocris Bioscience, Purinergic (P2Y) Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Highly potent P2Y12 antagonistFTY 720
Potent S1P receptor agonist; also immunosuppresentCinacalcet hydrochloride
Calcium-sensing receptor (CaSR) allosteric agonist; also CYP2D2 inhibitor and Ca2+ channel blocker; orally bioavailableAMG 837 hemicalcium salt
Potent free fatty acid receptor 1 (FFA1/GPR40) partial agonistUMB 68
GHB receptor ligandAZD 1283
High affinity P2Y12 antagonistEx 26
Potent and selective S1P1 receptor antagonistZQ 16
Selective GPR84 agonistIHR-Cy3
Potent fluorescent Smo antagonistRo 6842262
Potent LPA1 antagonistAMG 853
Potent dual CRTH2 and prostaglandin D2 (PGD2) receptor antagonistAM 4668
Potent FFA1 (GPR40) agonist
April 22 - 26, 2017
Chicago, IL, USA